Syndevrx, Inc. reported raising $16.3M in an amended private placement filing on March 20, 2017

Mar 22, 2017
Investments
Background Information
Syndevrx, Inc. develops treatments for metabolic-related diseases. Its product includes SDX-7320, a polymer conjugate of fumagillol that releases a pharmacologically active small molecule fumagillol derivative in vivo. The company was founded by James M. Shanahan and Bradley J. Carver and is headquartered in Cambridge, MA.